⚠️ Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only.
MAZDUTIDE
MAZDUTIDE
Couldn't load pickup availability
Mazdutide (IBI362)
Dual GLP-1R & GCGR Agonist – Research Grade
Mazdutide, also known as IBI362, is an investigational peptide currently under study for its potential applications in obesity, type 2 diabetes, and related metabolic disorders. It acts as a dual agonist of both the GLP-1 receptor (GLP-1R) and the glucagon receptor (GCGR)—two key targets in the regulation of appetite, energy expenditure, and glucose metabolism.
Mechanism of Action:
-
GLP-1R Agonism: Promotes insulin secretion, delays gastric emptying, and increases satiety—supporting glycemic control and weight loss.
-
GCGR Agonism: Stimulates lipid oxidation and hepatic glucose output—boosting energy expenditure and fat mobilization.
Potential Research Benefits:
-
Supports body weight reduction via dual pathways
-
Enhances insulin sensitivity and glycemic regulation
-
May aid in lipid metabolism and address conditions such as NAFLD (non-alcoholic fatty liver disease)
Research Status:
Developed by Innovent Biologics, Mazdutide has advanced through Phase 1 and 2 clinical trials with early data showing promising efficacy and tolerability.
Applications:
Mazdutide offers a valuable model for studying dual incretin and glucagon signaling and may aid in developing next-gen therapies for obesity, diabetes, and metabolic syndrome.
For research purposes only. Not for human consumption.
Share
